NHS Halts Gender-Affirming Hormone Treatment for New Teenage Patients
The National Health Service has suspended the prescription of gender-affirming hormone drugs to new patients under the age of 18, effective immediately. This decision follows a comprehensive review by NHS England into the treatment's effectiveness and safety for adolescents experiencing gender dysphoria.
Review Finds Insufficient Evidence for Treatment
The NHS England review concluded that the available evidence is too weak to determine whether masculinising or feminising hormones provide clear benefits or pose significant risks to children and teenagers with gender dysphoria. As a result, new referrals for these treatments have been paused from Monday, March 9, 2026.
Existing patients aged 16 and 17 who are currently receiving cross-sex hormones will continue their therapy, but each case must undergo individual clinical review to ensure appropriate care. The NHS emphasizes that specialist support, including mental health services and referrals to gender-specific care, remains available for all under-18s managing gender incongruence.
Irreversible Changes and Health Concerns
Gender-affirming hormone treatments can cause permanent physiological changes. Testosterone may lead to voice deepening and facial hair growth, while oestrogen can initiate breast development. Long-term use of these hormones has been associated with temporary or permanent infertility, according to NHS guidelines.
The decision aligns with recommendations from the 2024 Cass Review, conducted by Baroness Hilary Cass, which advised "extreme caution" in prescribing such drugs to minors. The review suggested waiting until individuals reach 18 unless there is a clear clinical rationale for earlier intervention.
Broader Context of Youth Gender Care
This move follows earlier restrictions on puberty blockers, which were banned for under-18s in 2024. A clinical trial investigating the impacts of puberty blockers on children as young as 10 was paused last month before any participants were recruited, due to concerns about "unquantified risks" and potential "long-term biological harms."
Professor James Palmer, national medical director for specialised services at NHS England, stated: "The NHS has exercised extreme caution when considering starting young people on this treatment—in accordance with the advice from Dr Cass—and as part of this action will now be pausing any new referrals for this treatment for 16 and 17-year-olds."
Consultation and Future Decisions
A 90-day public consultation has begun on proposals to remove gender-affirming hormone treatment as a routine NHS procedure for teenagers. The treatment pause will remain in effect throughout this consultation period and while NHS England reviews the expected thousands of responses before making a final policy decision.
The NHS continues to evaluate evidence regarding masculinising and feminising hormones for adults, indicating that this policy change specifically targets adolescent care. This development marks a significant shift in the approach to gender-affirming healthcare for young people in the United Kingdom.
